Evidence supporting the utilization of liquid biopsies in clinical practice continues to increase. With the introduction of many new liquid diagnostic assays, it is now more complex than ever to select the right test for each clinical intended use. It is essential to understand how the performance characteristics of liquid biopsy testing strategies impact the results and the extent to which patient management can be informed. In this presentation, we will review Sysmex Inostics’ highly sensitive circulating tumor DNA (ctDNA) technologies including OncoBEAM™ enhanced digital PCR and SafeSEQ NGS, which were initially developed by experts at the Johns Hopkins University School of Medicine [1, 2, 3]. OncoBEAM and SafeSEQ assays can detect the presence of very few ctDNA mutant molecules amidst a population of predominantly wildtype molecules, making them suitable for a wide variety of tumor types and clinical intended uses. In addition to targeted therapy selection, these technologies have enabled pioneering work in treatment response monitoring and detection of emerging resistance, as well as measurable residual disease detection. Recent evidence will be described which demonstrates how incorporating OncoBEAM and SafeSEQ ctDNA assessments into patient management can influence patient care decisions and may improve clinical outcomes.

Evidence supporting the utilization of liquid biopsies in clinical practice continues to increase. With the introduction of many new liquid diagnostic assays, it is now more complex than ever to select the right test for each clinical intended use. It is essential to understand how the performance characteristics of liquid biopsy testing strategies impact the results and the extent to which patient management can be informed. In this presentation, we will review Sysmex Inostics’ highly sensitive circulating tumor DNA (ctDNA) technologies including OncoBEAM™ enhanced digital PCR and SafeSEQ NGS, which were initially developed by experts at the Johns Hopkins University School of Medicine [1, 2, 3]. OncoBEAM and SafeSEQ assays can detect the presence of very few ctDNA mutant molecules amidst a population of predominantly wildtype molecules, making them suitable for a wide variety of tumor types and clinical intended uses. In addition to targeted therapy selection, these technologies have enabled pioneering work in treatment response monitoring and detection of emerging resistance, as well as measurable residual disease detection. Recent evidence will be described which demonstrates how incorporating OncoBEAM and SafeSEQ ctDNA assessments into patient management can influence patient care decisions and may improve clinical outcomes.

Evidence supporting the utilization of liquid biopsies in clinical practice continues to increase. With the introduction of many new liquid diagnostic assays, it is now more complex than ever to select the right test for each clinical intended use. It is essential to understand how the performance characteristics of liquid biopsy testing strategies impact the results and the extent to which patient management can be informed. In this presentation, we will review Sysmex Inostics’ highly sensitive circulating tumor DNA (ctDNA) technologies including OncoBEAM™ enhanced digital PCR and SafeSEQ NGS, which were initially developed by experts at the Johns Hopkins University School of Medicine [1, 2, 3]. OncoBEAM and SafeSEQ assays can detect the presence of very few ctDNA mutant molecules amidst a population of predominantly wildtype molecules, making them suitable for a wide variety of tumor types and clinical intended uses. In addition to targeted therapy selection, these technologies have enabled pioneering work in treatment response monitoring and detection of emerging resistance, as well as measurable residual disease detection. Recent evidence will be described which demonstrates how incorporating OncoBEAM and SafeSEQ ctDNA assessments into patient management can influence patient care decisions and may improve clinical outcomes.

Tumor-derived DNA is present in body fluids of cancer patients. Hence, liquid profiling is a promising minimal-invasive tool with great diagnostic and monitoring potential. It can complement invasive biopsies that provide only a snapshot of an often heterogeneous tumor. In contrast, repeated liquid profiling can track changes over time and detect tumor resistance occurring during therapy. Here, we share our latest results on liquid profiling in blood and saliva of head and neck cancer patients.

Tumor-derived DNA is present in body fluids of cancer patients. Hence, liquid profiling is a promising minimal-invasive tool with great diagnostic and monitoring potential. It can complement invasive biopsies that provide only a snapshot of an often heterogeneous tumor. In contrast, repeated liquid profiling can track changes over time and detect tumor resistance occurring during therapy. Here, we share our latest results on liquid profiling in blood and saliva of head and neck cancer patients.

Tumor-derived DNA is present in body fluids of cancer patients. Hence, liquid profiling is a promising minimal-invasive tool with great diagnostic and monitoring potential. It can complement invasive biopsies that provide only a snapshot of an often heterogeneous tumor. In contrast, repeated liquid profiling can track changes over time and detect tumor resistance occurring during therapy. Here, we share our latest results on liquid profiling in blood and saliva of head and neck cancer patients.

The approval of liquid biopsies (LB) for mutation detection of resistances in non-small cell lung cancer (NSCLC) was the start of a new and increasing field in the molecular pathology. The minimal-invasive analysis of circulating tumor DNA (ctDNA) from blood can be an alternative approach to identify patients carrying therapeutic relevant mutations. Beside the great potential of the LB approach, there are several drawbacks. The successful use of LB for the detection of druggable mutations is influenced by a number of variables that are still not fully understood (e.g. origin and release of cfDNA, conditions during sampling). Therefore, a deep understanding of the entire workflow and highly standardized protocols are essential to ensure reliable and reproducible results for the benefit of correct patient stratification.

The approval of liquid biopsies (LB) for mutation detection of resistances in non-small cell lung cancer (NSCLC) was the start of a new and increasing field in the molecular pathology. The minimal-invasive analysis of circulating tumor DNA (ctDNA) from blood can be an alternative approach to identify patients carrying therapeutic relevant mutations. Beside the great potential of the LB approach, there are several drawbacks. The successful use of LB for the detection of druggable mutations is influenced by a number of variables that are still not fully understood (e.g. origin and release of cfDNA, conditions during sampling). Therefore, a deep understanding of the entire workflow and highly standardized protocols are essential to ensure reliable and reproducible results for the benefit of correct patient stratification.

The approval of liquid biopsies (LB) for mutation detection of resistances in non-small cell lung cancer (NSCLC) was the start of a new and increasing field in the molecular pathology. The minimal-invasive analysis of circulating tumor DNA (ctDNA) from blood can be an alternative approach to identify patients carrying therapeutic relevant mutations. Beside the great potential of the LB approach, there are several drawbacks. The successful use of LB for the detection of druggable mutations is influenced by a number of variables that are still not fully understood (e.g. origin and release of cfDNA, conditions during sampling). Therefore, a deep understanding of the entire workflow and highly standardized protocols are essential to ensure reliable and reproducible results for the benefit of correct patient stratification.